




Acute Kidney Injury in Patients Treated with Immune Checkpoint Inhibitors 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2021-003467:e003467. 9 2021;J Immunother Cancer, et al. Gupta S
2 
 
Table of Contents                                                                              
                                                                                                                                                           
Supplemental Tables ....................................................................................................................................... 3-11 
Table S1. Collaborating Institutions…………………………………………………………………………..……………...3  
Table S2. Criteria for ICPi-AKI…………………………………………...……………………………….........……….……4 
Table S3. Kidney Disease: Improving Global Outcomes (KDIGO) Criteria for Acute Kidney Injury …......................5 
Table S4. Characteristics of Biopsied versus Non-Biopsied Patients with ICPi-AKI……...........................................6 
Table S5. Clinical Features of Patients Receiving Non-Corticosteroid Immunosuppression …................................7 
Table S6. Characteristics of ICPi-AKI Patients with and without Renal Recovery…………………………….............8-9 
Table S7. Characteristics of Patients Rechallenged Versus Not Rechallenged after ICPi-AKI……….……………..10 
Table S8. Characteristics of Patients with and without Recurrent ICPi-AKI after Rechallenge...….….……………..11 
 
Supplemental Figures……………………………………..…………………………………………………..…………...12-19 
Figure S1. Participating Sites in ICPi-AKI Consortium. ………………......................................................................12 
Figure S2. ICPi Initiation by Year among Patients with and without ICPi-AKI………………….................................13 
Figure S3. Risk Factors for Stage 2 ICPi-AKI or Higher...........................................................................................14 
Figure S4. Predictors of Renal Recovery among Patients Treated with Corticosteroids.……..…………………......15 
Figure S5. Flowchart of Patients with ICPi-AKI…………………………………...………………….……………….…..16 
Figure S6. Months from ICPi-AKI to Rechallenge.………….....................................................................................17 
Figure S7. Survival among Patients Rechallenged versus Not Rechallenged…………………..……………….…....18 










BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2021-003467:e003467. 9 2021;J Immunother Cancer, et al. Gupta S
3 
 
Table S1: Collaborating Institutions 
 
Collaborating Institution  Location No. ICPi-AKI 
cases (n=429) 
United States   
Brigham and Women’s Hospital/Dana-Farber Cancer 
Institute 
Boston, MA 20 
Duke University Durham, NC 14 
Massachusetts General Hospital Boston, MA 42 
Mayo Clinic Rochester, MN 24 
MD Anderson Cancer Center Houston, TX 22 
Memorial Sloane Kettering Cancer Center New York, NY 18 
Mt. Sinai New York, NY 5 
Northwell Health System Long Island, NY 15 
Northwestern Chicago, IL 13 
Ohio State University Columbus, Ohio 36 
Stanford Healthcare Palo Alto, CA 22 
University Hospitals Cleveland Medical Center Cleveland, OH 14 
University of Alabama Birmingham  Birmingham, AL 6 
University of California, Los Angeles Los Angeles, CA 6 
University of California, San Francisco San Francisco, CA 11 
University of Florida, Gainesville Gainesville, FL 7 
University of Miami Miami, FL 7 
University of Pennsylvania Philadelphia, PA 5 
University of Virginia  Charlottesville, VA 7 
University of Washington Seattle, WA 12 
International    
Charite Hospital Berlin, Germany 11 
Chi-Mei Medical Center Tainan, Taiwan 10 
Geneva University Hospital Geneva, Switzerland 7 
Guy’s and St. Thomas NHS Hospital London, England 28 
Heidelberg University Heidelberg, Germany 2 
Pitie-Salpetriere Hospital Paris, France 7 
Sheba Medical Center Ramat Gan, Israel 8 
University of Toronto Toronto, Canada 6 
Universitair Ziekenhuis Leuven Leuven, Belgium 14 
Vall d’Hebron University Hospital Barcelona, Spain 30 
 
Abbreviations: ICPI-AKI, immune checkpoint-inhibitor associated acute kidney injury 
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Table S2: Criteria for ICPi-AKI 
 
AKI that was directly attributed to the ICPi by the treating provider AND either 
of the following criteria: 
Criteria 1: Increase in SCr ≥ 100% from baseline OR treatment with RRT 
Criteria 2: Increase in SCr ≥50% from baseline AND at least one of the following: 
1) ATIN on biopsy  
2) ICPi held for at least one cycle due to concern for ICPi-AKI 
3) Treatment with corticosteroids due to concern for ICPi-AKI 
 
Abbreviations: AKI, acute kidney injury; ATIN, acute tubulointerstitial nephritis; ICPi, immune checkpoint inhibitor; 
RRT, renal replacement therapy; SCr, serum creatinine.  
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Table S3: Kidney Disease: Improving Global Outcomes (KDIGO) Criteria for Acute Kidney Injury 
 
Stage of AKI Serum Creatinine 
Stage 1 1.5-1.9x baseline  
Stage 2 2-2.9x baseline 
Stage 3 ≥3x baseline OR initiation of RRT 
 
Abbreviations: RRT, renal replacement therapy. Data on urine output were not available and were therefore not 
considered as part of AKI staging. Based on the KDIGO criteria.1   
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Table S4: Characteristics of Biopsied versus Non-Biopsied Patients with ICPi-AKI 





Age at ICPi initiation, yrs, median (IQR) 65 (58-73) 69 (60-75) 0.05 
Male, n (%) 85 (56.3) 181 (65.1) 0.08 
Race, n (%)   0.08 
    White 132 (87.4) 219 (78.8)  
    Black 9 (6.0) 18 (6.5)  
    Asian 5 (3.3) 16 (5.8)  
    Other/Unknown 5 (3.3) 25 (9.0)  
Comorbidities, n (%)    
   Hypertension 77 (60.0) 174 (62.6) 0.02 
   Diabetes 28 (18.5) 49 (17.6) 0.90 
   CHF 6 (4.0) 11 (4.0) 0.99 
   COPD 16 (10.6) 29 (10.4) 0.99 
   Cirrhosis 2 (1.3) 9 (3.2) 0.34 
Body mass index, median (IQR) 25.6 (21.9-29.4) 26.4 (23.2-30.6) 0.08 
Baseline SCr (mg/dL) 0.9 (0.76-1.16) 1.0 (0.8-1.26) 0.04 
Baseline eGFR,1 ml/min per 1.73 m2    
   Median (IQR) 76.5 (59.7-92.1) 71.5 (55.7-89.6) 0.06 
   eGFR Categories, n (%)   0.15 
      ≥90 47 (31.1) 64 (23.0)  
      60-89  65 (43.1) 127 (45.7)  
     45-59 27 (17.9) 45 (16.2)  
     30-44 10 (6.6) 33 (11.9)  
    <30 2 (1.3) 9 (3.2) 0.27 
Autoimmune Disease, n (%) 20 (13.2) 27 (9.7) 0.26 
Extrarenal irAE,2 n (%) 56 (37.1) 145 (52.2) 0.003 
Malignancy, n (%)   0.21 
   Melanoma 36 (23.8) 68 (24.5)  
   Lung  49 (32.5) 77 (27.7)  
   Genitourinary 27 (17.9) 73 (26.3)  
   Other 39 (25.8) 60 (21.6)  
PPI,3 n (%) 82 (39.4) 69 (31.2) 0.09 
Concomitant nephrotoxic chemotherapy,4 n (%)   
    Cisplatin 4 (2.7) 3 (1.1) 0.25 
    VEGF/TKI 3 (2.0) 20 (65.0) 0.02 
ICPi, 5 n (%)    
    Anti-CTLA-4 34 (22.5) 69 (24.8) 0.64 
    Anti-PD-1 120 (79.5) 227 (81.7) 0.58 
    Anti-PD-L1 14 (9.3) 28 (10.1) 0.87 
    Combo anti-CTLA-4 + anti-PD-1/ PD-L1 34 (22.5) 65 (23.4) 0.90 
Initial ICPi-AKI episode by stage,5 n (%)   <0.001 
    Stage 1 18 (11.9) 59 (21.2)  
    Stage 2 40 (26.5) 104 (37.4)  
    Stage 3 93 (61.6) 115 (41.4)  
Nephrologist involved, n (%) 147 (97.4) 214 (77.0) <0.001 
Data are shown as median (IQR) and n (%). Abbreviations: CHF, congestive heart failure; Combo, combination 
therapy; COPD, chronic obstructive pulmonary disease; CTLA-4, cytotoxic T lymphocyte–associated antigen 4; 
eGFR, estimated glomerular filtration rate; ICPi, immune checkpoint inhibitor; IQR, interquartile range; irAE, immune-
related adverse event;  PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; PPI, proton pump 
inhibitor; SCr, serum creatinine; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor. 
 
1Baseline eGFR calculated based on Chronic Kidney Disease-Epidemiology Collaboration equation.2 
2Extrarenal irAEs were assessed prior to (>14 days) or concomitant (within 14 days before or after) with ICPi-AKI 
diagnosis  
3PPIs were assessed in the 14 days preceding ICPi-AKI. 
4Concomitant chemotherapies were assessed in the 30 days preceding ICPi-AKI. 
5AKI stages are defined by Kidney Disease: Improving Global Outcomes criteria.1 
 
Data on body mass index are missing in 1 patient. All other data are complete.  
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AKI to Last 
Follow-up or 
Death 
72M Melanoma Ipi/Nivo  Infliximab  Yes No -- Alive 152 
73M Colon  PD-L1   Tocilizumab Yes No -- Alive 524 
69M Melanoma Ipi/Nivo  MMF Yes Yes Yes Alive 347 
50F Melanoma CTLA-4/PD-1  MMF Yes No -- Alive 584 
72M Melanoma Ipi/Nivo  Infliximab Yes Yes Yes Deceased 200 
33F Melanoma Ipi  Infliximab Yes No  -- Alive 1191 
56F Lung Adeno Pembro ATIN MMF No No -- Alive 119 
66M HCC Atezo  MMF Yes No -- Deceased 53 
46M Lung Adeno Pembro ATIN Infliximab No No -- Alive 283 
60M Lung Adeno Pembro ATIN MMF No No  -- Alive 688 
76M Lung Adeno Pembro  MMF No No -- Deceased 141 
71F Gastric Adeno Pembro Membranous with 
lupus-like features 
IVIG No Yes Yes Deceased 38 
51M HCC Nivo ATIN, chronic TMA, 
IC-mediated GN 
Infliximab No Yes Yes Alive 1014 
60M RCC Ipi/Nivo  MMF No No -- Deceased 17 
68F Lung SCC Atezo  MMF No No -- Deceased 7 
66M RCC Ipi/Nivo  MMF Yes No -- Alive 132 
68M Melanoma Ipi/Nivo ATIN MMF Yes No -- Deceased 69 
63M Sarcoma Ipi/Nivo ATIN, IgA 
Nephropathy 
MMF No No -- Deceased 108 
57F Melanoma Ipi/Nivo Pauci-immune GN PLEX, Rituximab No No -- Alive 297 
52F Lung Adeno Durva Pauci-immune GN Rituximab No No -- Alive 150 
81M Melanoma Nivo AA Amyloidosis Colchicine No No -- Deceased 130 
42M Rectal Pembro AA Amyloidosis Tocilizumab No No -- Alive 555 
 
Abbreviations: Adeno, adenocarcinoma; Atezo, atezolizumab; ATIN, acute tubulointerstitial nephritis; Durva, durvalumab; F, female; GBM, glioblastoma 
multiforme; GN, glomerulonephritis; HCC, hepatocellular carcinoma; IC, immune complex; ICPi-AKI, immune checkpoint inhibitor-associated acute kidney injury; 
Ipi, Ipilimumab; IVIG, intravenous immunoglobulin; M, male; MMF, mycophenolate mofetil; Nivo, Nivolumab; Pembro, Pembrolizumab; PLEX, plasmapheresis; 
RCC, renal cell carcinoma; RCT, randomized clinical trial; SCC, small cell cancer; TMA, thrombotic microangiopathy. 
 
1Renal recovery is defined as return of SCr ≤50% of baseline within 90 days of ICPi-AKI. 
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Table S6: Characteristics of ICPi-AKI Patients with and without Renal Recovery 
  Renal Recovery  
Characteristic All patients (n=429) Yes (n=276) No (n=153) P Value 
Age (yrs), median (IQR) 68 (59-75) 69 (60-75) 65 (58-74) 0.14 
Sex, n (%)     
   Male 266/429 (62.0) 185/266 (69.6) 81/266 (30.5) 0.005 
  Female 163/429 (38.0) 91/163 (55.8) 72/163 (44.2)  
Race, n (%)    0.04 
  White 351/429 (81.8) 234/351 (66.7) 117/351 (33.3)  
  Non-White 78/429 (18.2) 42/78 (53.9) 36/78 (46.2)  
Hypertension, n (%)    0.36 
  Yes 251/429 (58.5) 166/251 (66.1) 85/251 (33.9)  
  No 178/429 (41.5) 110/178 (61.8) 68/178 (38.2)  
Diabetes, n (%)    0.43 
  Yes 77/429 (17.9) 53/77 (68.8) 24/77 (31.2)  
  No 352/429 (82.1) 223/352 (63.4) 129/352 (36.7)  
Baseline eGFR1 (ml/min/1.73m2)     
  Median (IQR) 73 (57-90) 68 (53-85) 86 (65-98) <0.001 
  eGFR categories    <0.001 
      ≥90  111/429 (25.9) 49/111 (44.1) 62/111 (55.9)  
     60-89  192/429 (44.8) 128/192 (66.7) 64/192 (33.3)  
     45-59 72/429 (16.8) 56/72 (76.4) 17/72 (23.6)  
     <45  54/429 (12.6) 44/54 (81.5) 10/54 (18.5)  
Malignancy, n (%)    <0.001 
  Lung 126/429 (29.4) 62/126 (49.2) 64/126 (50.8)  
  Other 303/429 (70.6) 214/303 (70.6) 89/303 (29.4)  
PPI,2 n (%)    0.23 
  Yes 208/429 (48.5) 140/208 (67.3) 68/208 (32.7)  
  No 221/429 (51.5) 136/221 (61.5) 85/221 (38.5)  
NSAIDs,2 n (%)    0.37 
  Yes 81/429 (18.9) 56/81 (69.1) 25/81 (30.9)  
  No 348/429 (81.1) 220/348 (63.2) 128/348 (36.8)  
Antibiotics,2 n (%)    0.49 
  Yes 40/429 (9.3) 28/40 (70.0) 12/40 (30.0)  
  No 389/429 (90.7) 248/389 (63.8) 141/389 (36.3)  
Receipt of PPI, NSAIDs, or Antibiotics, n (%)    0.05 
   Yes 266/429 (62.0) 181/266 (68.1) 85/266 (32.0)  
   No 163/429 (38.0) 95/163 (58.3) 68/163 (41.7)  
Receipt of concomitant nephrotoxic 
chemotherapies,3 n (%) 
   0.34 
   Yes 71/429 (16.6) 42/71 (59.2) 29/71 (40.8)  
   No 358/429 (83.4) 234/358 (65.4) 124/358 (34.6)  
Combination ICPi therapy,4 n (%)    0.03 
  Yes 99/429 (23.1) 73/99 (73.7) 26/99 (26.3)  
  No 330/429 (76.9) 203/330 (61.5) 127/330 (38.5)  
Extrarenal irAE,5 n (%)    0.09 
  Yes 201/429 (46.9) 138/201 (68.7) 63/201 (31.3)  
  No 228/429 (53.2) 138/228 (60.5) 90/228 (39.5)  
Concomitant extra-renal irAE, n (%)    0.03 
  Yes 114/429 (26.6) 83/114 (72.8) 31/114 (27.2)  
  No 315/429 (73.4) 193/215 (61.3) 122/315 (38.7)  
Days from ICPi initiation to AKI, n (%)    0.22 
  <30  55/429 (12.8) 36/55 (65.5) 19/55 (34.6)  
  30-59 56/429 (13.1) 39/56 (69.6) 17/56 (30.4)  
  60-89 64/429 (14.9) 47/64 (73.4) 17/64 (26.6)  
  ≥90 254/429 (59.2) 154/254 (60.6) 100/254 (39.4)  
ICPi-AKI stage,6 n (%)    <0.001 
  Stage 1 77/429 (17.9) 70/77 (90.1) 7/77 (9.1)  
  Stage 2 144/429 (33.6) 102/144 (70.8) 42/144 (29.2)  
  Stage 3 208/429 (48.5) 104/208 (50.0) 104/208 (50.0)  
Blood on urinalysis,7 n (%)    <0.001 
  <2+ 257/317 (81.1) 175/257 (68.1) 82/257 (31.9)  
  ≥2+ 60/317 (18.9) 27/60 (45.0) 33/60 (55.0)  
 Leukocyte esterase on urinalysis,7 n (%)    <0.001 
  <2+ 238/317 (75.1) 165/238 (69.3) 73/238 (30.7)  
  ≥2+ 79/317 (24.9) 37/79 (46.8) 42/79 (53.2)  
Urine protein:creatinine, g/g, n (%)    0.01 
  <1 162/206 (78.6) 108/162 (66.7) 54/162 (33.3)  
  ≥1 44/206 (21.4) 19/44 (43.2) 25/55 (56.8)  
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Eosinophilia, cells per µl, n (%)    0.60 
  <500 387/426 (90.8) 248/387 (64.1) 139/387 (35.9)  
  ≥500 39/426 (9.2) 27/39 (69.2) 12/39 (30.8)  
Nephrologist involved in treatment of AKI, n (%)    0.89 
  Yes 361/429 (84.1) 233/361 (64.5) 128/361 (35.5)  
  No 68/429 (15.9) 43/68 (63.2) 25/48 (36.8)  
Treatment with CS, n (%)    0.09 
  Yes 350/429 (81.6) 232/350 (66.3) 118/230 (3.37)  
  No 79/429 (18.4) 44/79 (55.7) 35/79 (44.3)  
    Treatment with CS within 3d of AKI, n (%)    0.01 
       Yes 160/347 (46.1) 117/160 (73.1) 43/160 (26.9)  
       No 187/347 (53.9) 112/187 (60.0) 75/187 (40.1)  
    SCr at CS initiation (mg/dL), median (IQR) 2.5 (2.0-3.7) 2.4 (2.0-3.6) 2.0 (1.5-2.6) 0.90 
    Received IV pulse CS, n (%)    0.01 
       Yes 100/350 (28.6) 56/100 (56.0) 44/100 (44.0)  
       No 250/350 (71.4) 176/250 (70.4) 74/250 (29.6)  
Initial daily oral CS dose (prednisone equivalent 
units, mg), median (IQR) 
60 (50-80) 60 (60-80) 60 (40-65) 0.12 
Nadir SCr after treatment8 (mg/dL), median 
(IQR) 
1.3 (1.1-1.7) 1.2 (1.0-1.5) 1.6 (1.3-2.1) <0.001 
 
Abbreviations: AKI, acute kidney injury; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CTLA-4, cytotoxic 
T lymphocyte–associated antigen 4; combo, combination therapy; CS, corticosteroid; eGFR, estimated glomerular 
filtration rate; irAEs, immune-related adverse events; ICPi, immune checkpoint inhibitor; IV, intravenous; NSAID, non-
steroidal anti-inflammatory drug; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; PPI, proton 
pump inhibitor; RRT, renal replacement therapy; SCr, serum creatinine. 
 
1Baseline eGFR calculated based on Chronic Kidney Disease-Epidemiology Collaboration equation.2 
2PPIs, NSAIDs, and antibiotics were assessed in the 14 days preceding AKI. 
3Refers to treatment with nephrotoxic chemotherapies in the 30 days preceding AKI, including cisplatin, carboplatin, 
tyrosine kinase and/or vascular endothelial growth factor inhibitors, pemetrexed, BRAF inhibitors, and paclitaxel 
4Denotes whether the patient ever received combination therapy prior to AKI. 
5Extrarenal irAEs were assessed prior to (>14 days) or concomitant (within 14 days before or after) with ICPi-AKI. 
6AKI stages are defined by Kidney Disease: Improving Global Outcomes criteria.1 
7From initial dipstick at the time of AKI diagnosis. 
8Within 3 months of AKI diagnosis. 
 
112 patients (26.1%) were missing data on blood and leukocyte esterase on urine dipstick, 223 (52.0%) were missing 
data on urine protein:Cr ratio, 3 (0.7%) were missing data on eosinophils, and 3 (0.7%) were missing data on the 
timing of corticosteroid treatment. All other data are complete. 
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Table S7: Characteristics of Patients Rechallenged Versus Not Rechallenged after ICPi-AKI 
 
Abbreviations: AKI, acute kidney injury; ATIN, acute tubulointerstitial nephritis; ICPi, immune checkpoint inhibitor; 
RRT, renal replacement therapy; SCr, serum creatinine. 
 
1Baseline eGFR calculated based on Chronic Kidney Disease-Epidemiology Collaboration equation.2  
2Extrarenal irAEs were assessed prior to (>14 days) or concomitant (within 14 days before or after) with ICPi-AKI. 
3AKI stages are defined by Kidney Disease: Improving Global Outcomes criteria.1 
4Lowest SCr in the 90 days following ICPi-AKI onset. 
5Defined as a return of SCr to ≤50% of the baseline SCr within 90 days of ICPi-AKI.  
  







Age at ICPi initiation, yrs, median (IQR) 68 (59-75) 66 (60-74) 68 (59-75) 0.62 
Male, n (%) 266 (62.0) 81 (66.9) 185 (60.1) 0.22 
Race, n (%)    0.21 
    White 351 (81.8) 104 (86.0) 247 (80.2)  
    Nonwhite 78 (18.2) 17 (14.1) 61 (19.8)  
Malignancy, n (%)    0.06 
    Lung 126 (29.4) 27 (22.3) 99 (32.1)  
    Melanoma 104 (24.2) 39 (32.2) 65 (21.1)  
    Genitourinary 100 (23.3) 28 (23.1) 72 (23.4)  
    Other 99 (23.1) 27 (22.3) 72 (23.4)  
Baseline eGFR,1 ml/min per 1.73 m2, 
median (IQR) 
73.3 (57.1-90.4) 73.3 (60.7-88.1) 73.6 (55.4-91.5) 0.97 
Autoimmune disease, n (%) 47 (11.0) 13 (10.7) 34 (11.0) 0.99 
Extrarenal irAE,2 n (%) 201 (46.9) 58 (47.9) 143 (46.4) 0.83 
Initial ICPi-AKI episode by stage,3 n (%)    0.002 
    AKI stage 1 77 (18.0) 27 (22.3) 50 (16.2)  
    AKI stage 2 144 (33.6) 52 (43.0) 92 (30.0)  
    AKI stage 3 208 (48.5) 42 (34.7) 166 (53.9)  
RRT, n (%) 33 (7.7) 3 (2.5) 30 (9.7) 0.001 
Rechallenged with same initial class of 
ICPi, n (%) 
--- 98 (81.0) ---  
Rechallenged with a different class of 
ICPi, n (%) 
--- 23 (19.0) ---  
Treated with corticosteroids, n (%) 350 (81.6) 96 (79.3) 254 (82.5) 0.50 
Biopsied, n (%) 151 (35.2) 34 (28.1) 117 (38.0) 0.06 
     ATIN on Biopsy, n (%) 125 (82.8) 26 (76.5) 99 (84.6) 0.30 
Nadir SCr,4 mg/dl, median (IQR)  1.3 (1.1-1.7) 1.2 (1.0-1.5) 1.4 (1.1-1.8) 0.001 
Renal recovery,5 n (%) 276 (64.3) 93 (76.8) 183 (59.4) <0.001 
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Table S8: Characteristics of Patients with and without Recurrent ICPi-AKI after Rechallenge 
 
Data are shown as median (IQR) and n (%). 
 
Abbreviations: AKI, acute kidney injury; ATIN, acute tubulointerstitial nephritis; CTLA-4, cytotoxic T lymphocyte–
associated antigen 4; CS, corticosteroid; ICPi, immune checkpoint inhibitor; IV, intravenous; irAE, immune-related 
adverse event; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; RRT, renal replacement 
therapy; SCr, serum creatinine. 
 
1Defined as a return of SCr to ≤50% of the baseline SCr 
2Extrarenal irAEs were assessed prior to (>14 days) or concomitant (within 14 days before or after) with ICPi-AKI. 
3AKI stages are defined by Kidney Disease: Improving Global Outcomes criteria.1 
42 patients had AKI requiring RRT and were not liberated. 
5One patient received Anakinra, and another received infliximab. 
6Defined as a return of SCr to ≤50% of the baseline SCr within 90 days of ICPi-AKI.   













Days, initial ICPi-AKI to rechallenge, median (IQR) 56 (33-121) 58 (37-105) 56 (33-122) 0.86 
Renal Recovery from initial ICPi-AKI,1 n (%) 93 (76.9) 15 (75.0) 78 (77.2) 0.78 
SCr at rechallenge (mg/dL), median (IQR) 1.3 (1.1-1.5) 1.3 (1.1-1.6) 1.3 (1.1-1.5) 0.46 
On CS at rechallenge, n (%) 59 (48.8) 11 (55.0) 48 (47.5) 0.63 
    Prednisone dose (mg/day), median (IQR) 10 (20-53) 10 (8-30) 10 (8-20) 0.76 
Rechallenge Regimen, n (%)    0.99 
   CTLA-4 17 (14.0) 3 (14.3) 14 (13.9)  
   PD-1  89 (73.6) 15 (71.4) 74 (73.3)  
   PD-L1 10 (8.3) 1 (4.8) 9 (8.9)  
Rechallenged with same initial class of ICPi, n (%) 98 (81.0) 14 (70.0) 84 (83.2) 0.34 
Rechallenged with a different class of ICPi, n (%) 23 (19.0) 6 (30.0) 17 (16.8)  
Age at ICPi initiation (yrs), median (IQR) 67 (61-73) 67 (62-72) 66 (60-74) 0.92 
Female, n (%) 81 (66.9) 14 (70.0) 67 (66.3) 0.99 
Autoimmune Disease, n (%) 13 (10.7) 1 (5.0) 23 (11.9) 0.69 
Extrarenal irAE,2 n (%) 58 (47.9) 11 (55.0) 47 (46.5) 0.63 
Stages of initial ICPi-AKI,3 n (%)    0.67 
    Stage 1 AKI 27 (22.3) 6 (30.0) 21 (20.8)  
    Stage 2 AKI 52 (43.0) 8 (40.0) 44 (43.6)  
    Stage 3 AKI 42 (34.7) 6 (30.0) 36 (35.6)  
Biopsied, n (%) 34 (28.1) 7 (35.0) 27 (26.7) 0.59 
    ATIN on biopsy, n (%) 26 (76.5) 3 (42.9) 23 (85.2) 0.04 
Died, n (%) 44 (36.4) 12 (60.0) 32 (31.7) 0.02 





SCr at recurrent ICPi-AKI (mg/dL), median (IQR) --- 1.0 (0.9-1.1) --- --- 
Stages of recurrent ICPi-AKI, n (%)     
    Stage 1 AKI --- 4 (20) --- --- 
    Stage 2 AKI --- 8 (40) --- --- 
    Stage 3 AKI4 --- 8 (40) --- --- 
ICPi held at time of AKI, n (%) --- 20 (100) --- --- 
ICPi-AKI treated with CS, n (%) --- 14 (70) --- --- 
     Days from ICPi-AKI to CS, median (IQR) --- 5 (3-13) --- --- 
     Received IV pulse CS, n (%) --- 1 (7.1) --- --- 
     Initial daily oral CS dose (mg of prednisone) --- 40 (40-60) --- --- 
     RRT at the time of CS, n (%) --- 0 (0) --- --- 
Received non-CS immuno-suppressant,5 n (%) --- 2 (10) --- --- 
Renal Recovery,6 n (%) --- 10 (50) --- --- 
     Days to Renal Recovery, median (IQR) --- 34 (27-38) --- --- 
Nadir SCr (mg/dL),7 median (IQR) --- 1.4 (1.1-1.7) --- --- 
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Figure S3: Risk Factors for Stage 2 ICPi-AKI or Higher 
 
 
n=781 (352 patients with stage 2 or 3 ICPi-AKI; 429 patients without ICPi-AKI). All model covariates are shown in the 
figure. 
 
*Denotes PPI use within 14 days preceding ICPi-AKI among those with ICPi-AKI, and PPI use at the time of ICPi 
initiation among patients without ICPi-AKI. 
**Extrarenal irAEs were assessed prior to (>14 days) or concomitant (within 14 days before or after) with ICPi-AKI 
diagnosis among patients with ICPi-AKI, and at any time after ICPi initiation among patients without ICPi-AKI. 
 
Abbreviations: eGFR, estimated glomerular filtration rate; ICPi, immune checkpoint inhibitor; irAEs, immune-related 
adverse events; PPI, proton pump inhibitor. 
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Figure S4: Predictors of Renal Recovery among Patients Treated with Corticosteroids 
 
n=334 (including 227 patients with renal recovery). Renal recovery was defined as a return of serum creatinine to 
≤50% of the baseline value within 90 days of ICPi-AKI. Patients who were died within 14 days of ICPi-AKI (n=16) 
were excluded. All model covariates are shown in the figure. 
 
*Denotes receipt of NSAIDs, PPIs, antibiotics in the 14 days preceding ICPi-AKI. 
**Extrarenal irAEs were assessed as occurring concomitantly (within 14 days before or after) with ICPi-AKI. 
 
Abbreviations: AKI, acute kidney injury; ATIN, acute tubulointerstitial nephritis; Cr, creatinine; eGFR, estimated 
glomerular filtration rate; ICPi, immune checkpoint inhibitor; irAE, immune-related adverse events; NSAIDs, non-
steroidal anti-inflammatory drugs; PPI, proton pump inhibitor. 
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Figure S5: Flowchart of Patients with ICPi-AKI 
 
 
Stages of AKI are defined according to Kidney Disease: Improving Global Outcomes criteria.1 Renal recovery is 
defined as a return of serum creatinine to ≤50% of the baseline value within 90 days of ICPi-AKI. 
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121 patients were rechallenged at a median of 1.8 months (IQR, 1.1-4.0) following ICPi-AKI 
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Figure S7: Survival Among Patients Rechallenged versus Not Rechallenged  
 
Kaplan-Meier curves and multivariable Cox regression models were used to estimate the effect of ICPi 
rechallenge versus no ICPi rechallenge on overall survival. To eliminate the potential for immortal time 
bias, we limited this analysis to patients who survived at least 90 days after the initial ICPi-AKI event, and 
we compared the survival of patients rechallenged in the first 90 days to those not rechallenged in the first 
90 days (panels A and B). We repeated this analysis in patients who survived at least 180 days following 
the initial ICPi-AKI event, thereby comparing the survival of patients rechallenged in the first 180 days to 
those not rechallenged in the first 180 days (panels C and D). 
 
1Renal recovery is defined as a return of serum creatinine to ≤50% of the baseline value within 90 days of 
ICPi-AKI.  All model covariates are shown in the figure. 
 
Abbreviations: HR, hazard ratio. 
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Of the 429 patients in this study, 24 (5.6%) were reported in a study of biomarkers and clinical 
features of ICPi-AKI;3 10 (2.3%) were reported in a study of AKI among patients receiving 
ICPis;4 1 (0.2%) was reported in a study of ICPi-AKI after PD-L1 inhibitors;5 21 (4.9%) were 
included in a study of patients describing rapid corticosteroid taper versus standard of care for 
ICPi-AKI;6 2 (0.5%) were reported in a study of AA amyloidosis attributed to ICPis;7 30 (7.0%) 
were reported in 3 publications describing patients with ICPi-AKI admitted to a hospital in 
Spain;8–10 3 (0.7%) were included in a study of ICPi-AKI patients with lesions other than acute 
tubulointerstitial nephritis on biopsy;11 7 (1.6%) with ICPi-AKI and 9 (2.1%) control patients 
without ICPi-AKI were included in 2 publications, neither of which assessed renal toxicities from 
ICPis;12,13 and 2 (0.5%) were included in a study of ICPi-AKI in Canada.14 The 138 patients with 
ICPi-AKI described in our prior multicenter study15 were not included in the current study. 
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Did the patient have a ≥100% increase (i.e., Yes
doubling) of serum creatinine (SCr) relative to No
baseline, or the need for renal replacement therapy?
Note: Baseline SCr refers to the nearest value prior
to initiation of immune checkpoint inhibitor (ICPi)
therapy
Was the AKI attributed to the ICPi by the treating Yes
provider? No
*The patient must have received ICPi within 180 days
of the AKI
STOP, THIS PATIENT IS NOT ELIGIBLE
THIS PATIENT IS ELIGIBLE, please proceed with data entry
Did the patient have a ≥50% increase in SCr from Yes
baseline? No
Note: Baseline SCr refers to the nearest value prior
to initiation of immune checkpoint inhibitor (ICPi)
therapy
Was the AKI attributed the ICPi by the treating Yes
provider? No
Does the patient fulfill one or more of the following Yes
criteria? No
1) Tubulointerstitial nephritis on biopsy 
2) ICPi was held for at least one cycle due to concern
for ICPi-AKI
3) The patient was treated with steroids due to
concern for ICPi-AKI
Which of the following criteria did the patient meet Tubulointerstitial nephritis on biopsy
(check one or more) ICPi was held for at least one cycle due to
concern for ICPi-AKI
The patient was treated with steroids due to
concern for ICPi-AKI
STOP, THIS PATIENT IS NOT ELIGIBLE
Did this patient have a history of a renal transplant? Yes
No
STOP, THIS PATIENT IS NOT ELIGIBLE
THIS PATIENT IS ELIGIBLE, please proceed with data entry
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Demographics
Unless otherwise indicated, the timing of the data below refers to initiation of immune
checkpoint inhibitor (ICPi) therapy








Select assessment(s) of proteinuria performed within 6 None
months prior to initiation of ICPi therapy (if any Spot urine protein to creatinine ratio
were performed more than once, use the most recent Spot urine albumin to creatinine ratio
value) 24 hr urine collection
Urinalysis
Enter the most recent spot urine protein:Cr ratio
(g/g) prior to ICPi therapy __________________________________
For example, enter "3" if the patient had 3 g protein
per g of creatinine
Enter the most recent albumin:Cr ratio (mg/g) prior to
ICPi therapy __________________________________
For example, enter "30" if the patient had 30 mg 
albumin per gram of creatinine
Enter the most recent 24 hr urine collection for
protein (g/day) prior to ICPi therapy __________________________________
Enter the results of the most recent urine protein neg/trace






Pay careful attention to the units and enter the
weight in kg, not lbs
Height (cm)
__________________________________
Pay careful attention to the units and enter the
height in cm, not inches
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Baseline serum creatinine (SCr) . Please enter in
mg/dl __________________________________
(*Serum creatinine should be in mg/dl)
Note: Baseline SCr refers to the nearest value prior
to initiation of ICPi therapy
Was a CBC with differential performed within three Yes
months prior to initiation of ICPi therapy? No
What was the total white blood cell (WBC) count?
__________________________________
(If more than one CBC with diff was performed
within 3 months prior to ICPi initiation, use the
closest one)
What was the neutrophil percentage?  (enter as a
number between 0 to 100, and without a "%" sign) __________________________________
(If more than one CBC with diff was performed
within 3 months prior to ICPi initiation, use the
closest one)
What was the lymphocyte percentage?  (enter as a
number between 0 to 100, and without a "%" sign) __________________________________
(If more than one CBC with diff was performed
within 3 months prior to ICPi initiation, use the
closest one)
What was the eosinophil percentage? (enter as a number
between 0 to 100, and without a "%" sign) __________________________________
(If more than one CBC with diff was performed
within 3 months prior to ICPi initiation, use the
closest one)
What was the platelet count?  (enter as a two- or
three-digit number) __________________________________
(If more than one CBC with diff was performed
within 3 months prior to ICPi initiation, use the
closest one)
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Past medical history (check all that apply) Hypertension
Diabetes mellitus
Chronic kidney disease (eGFR < 60 ml/min/1.73m2 





Enter other relevant past medical history (e.g.,
history of solid organ transplantation) __________________________________




Enter cause of CKD
__________________________________
History of autoimmune disease (check all that apply) None
Type 1 diabetes mellitus
**Note, we are specifically looking for autoimmune Asthma
disease that was present PRIOR to initiation of ICPi Psoriasis
therapy, not an immune-related adverse event that Grave's Disease




Inflammatory bowel disease (UC or Crohn's)
Celiac disease
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ICPi Treatment
All questions in this section refer to ICPi therapy administered PRIOR to the initial episode of
AKI
Date of initiation of  ICPi therapy
__________________________________
Did the patient ever receive simultaneous (i.e., at Yes
the same point in time) combination therapy with a No
CTLA-4 inhibitor AND a PD-1/PD-L1 inhibitor prior to
AKI?
Check the CTLA-4 inhibitor the patient received ipilimumab (CTLA-4)




Check the PD-1/PD-L1 inhibitor the patient received nivolumab (PD-1)







Check all ICPis ever received prior to first episode ipilimumab (CTLA-4)









Check all ICPis received within 8 weeks prior to the ipilimumab (CTLA-4)
first episode of AKI.  If ICPi therapy had already tremelimumab (CTLA-4)
been completed/discontinued >8 weeks prior to AKI, nivolumab (PD-1)







Date of last ICPi dose prior to initial episode of AKI
__________________________________
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AKI clinical features
Was the patient hospitalized as a result of their Yes
ICPi-AKI? No
Was a nephrologist involved in the management of the Yes
ICPi-AKI? No
Did the patient have any EXTRA-renal immune-related Yes
adverse events in which the onset was prior to AKI? No
(defined as an onset occurring >14 days before AKI was
first detected)










Provide other immune related adverse event prior to
AKI __________________________________
Did the patient have any EXTRA-renal immune-related Yes
adverse events in which the onset was concurrent with No
the AKI?  (defined as an onset occurring within 14
days prior to or after AKI was first detected)
Select all extra-renal immune related adverse events Rash









Provide other immune related adverse events occurring
concomitantly with AKI __________________________________
Did the patient take any of the following within 14 Antibiotics
days preceding detection of AKI? NSAIDs
Proton pump inhibitors
Which antibiotic did patient receive?
__________________________________
Did the patient receive cisplatin within a month prior Yes
to AKI diagnosis? No
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Why was the AKI attributed to the ICPi instead of the
cisplatin? __________________________________
Did the patient receive a tyrosine kinase inhibitor Yes
(TKI) and/or a vascular endothelial growth factor No
(VEGF) inhibitor within a month prior to AKI (ex: aflibercept, axitinib, bevacizumab,
diagnosis? cabozantinib, dasatinib, erlotinib, gefitinib,
imatinib, levantinib, nilotinib, pazopanib,
ponatinib, ramucirumab, ranibizumab, regorafenib,
sorafenib, sunitinib)
Which tyrosine kinase and/or VEGF inhibitor did the aflibercept (Zaltrap)

















Which other TKI/VEGF inhibitor did the patient
receieve? __________________________________
Why was the AKI attributed to the ICPi instead of the
TKI/VEGF inhibitor? __________________________________
Did the patient receive another potentially Yes
nephrotoxic chemotherapy agent within a month prior to No
AKI diagnosis?
Which potentially nephrotoxic chemotherapy agent did
the patient receive? __________________________________
(ex: gemcitabine, carboplatin)
Why was the AKI attributed to the ICPi instead of the
chemotherapy agent? __________________________________
Was the patient already receiving glucocorticoids for Yes
an alternative condition when AKI was first detected? No
Enter the daily dose of glucocorticoids (in prednisone
equivalents) the patient was already receiving when __________________________________
AKI was first detected
A steroid conversion calculator can be found here:
https://www.mdcalc.com/steroid-conversion-calculator
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Enter the reason the patient was already receiving
glucocorticoids when AKI  was first detected (e.g., to  
treat an extra-renal immune related adverse event) __________________________________________
You indicated that this patient had a ≥50% (i.e.,
≥1.5-fold) increase in SCr relative to baseline. __________________________________
Enter the date the patient first had a ≥50% increase
in SCr.
You indicated that this patient had a ≥100% increase
(i.e., doubling) in SCr relative to baseline. Enter __________________________________
the date the patient first had a ≥100% increase in
SCr.
SCr (mg/dl) at time point when patient first fulfilled
criteria for AKI __________________________________
(Please ensure serum creatinine is in mg/dl)
Peak SCr (mg/dl) during AKI episode (limit to within 4
weeks of AKI diagnosis) __________________________________
(Please ensure serum creatinine is in mg/dl)
Quantification of proteinuria during AKI (check all none
that apply) spot urine protein:Cr ratio
spot urine albumin:Cr ratio (microalbumin)
24 hour urine collection for protein
(*Please indicate any quantification within 7 days
AFTER AKI onset)
Spot urine protein:Cr ratio (g/g) at AKI diagnosis
__________________________________
For example, enter "3" if the patient had 3 g protein (*Please indicate value within 7 days AFTER AKI
per gram of creatinine onset)
Spot urine albumin:Cr ratio (mg/g) at AKI diagnosis
__________________________________
 (*Please indicate value within 7 days AFTER AKI
onset)
For example, enter "30" if the patient had 30 mg
albuminuria per gram of creatinine
24 hr urine collection for protein (g/day) at AKI
diagnosis __________________________________
(*Please indicate value within 7 days AFTER AKI
onset)
Urinalysis (urine dipstick) performed? Yes
No





BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer












N/A (taken from foley catheter)
Review of urine sediment with microscopy performed? Yes
(either sent to the clinical lab or reviewed manually No
by a nephrologist)
List all urine microscopy findings at AKI diagnosis
__________________________________
(*Please include findings like 10-20 WBCs per hpf,
RBCs, casts, renal tubular epithelial cells, etc.)
Was a CBC with differential performed within one week Yes
before or after AKI diagnosis? No
What was the total white blood cell (WBC) count?
__________________________________
(if more than one CBC with diff was performed
within 1 week before or after AKI diagnosis, please
list the closest value)
What was the neutrophil percentage? (enter as a number
between 0 to 100, and without a "%" sign) __________________________________
(if more than one CBC with diff was performed
within 1 week before or after AKI diagnosis, please
list the closest value)
What was the lymphocyte percentage?  (enter as a
number between 0 to 100, and without a "%" sign) __________________________________
(if more than one CBC with diff was performed
within 1 week before or after AKI diagnosis, please
list the closest value)
What was the eosinophil percentage?  (enter as a
number between 0 to 100, and without a "%" sign) __________________________________
(If more than one CBC with diff was performed
within 1 week before or after AKI diagnosis, use
the closest one)
What was the platelet count?
__________________________________
(if more than one CBC with diff was performed
within 1 week before or after AKI diagnosis, please
list the closest value)
Renal ultrasound performed within 14 days of AKI Yes
diagnosis? No
Right kidney size (cm)
__________________________________
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Left Kidney size (cm)
__________________________________
Was a renal biopsy performed? Yes
No
Paste the entire biopsy report,  including light
microscopy, immunofluorescence,  and electron  
microscopy (remove patient name and MRN) __________________________________________
Was tubulointerstitial nephritis the primary lesion on Yes
biopsy? No
Did another lesion co-occur with tubulointerstitial Yes
nephritis on biopsy? No






Acute tubular necrosis/injury (ATN/ATI)
Other
Please describe the other lesion on biopsy
__________________________________
Antinuclear antibody (ANA) Not performed
Negative
Positive
(*Only refers to testing performed within 2 weeks




(*Only refers to testing performed within 2 weeks
before or after AKI onset)
C3 level Not performed
Normal/High
Low
(*Only refers to testing performed within 2 weeks
before or after AKI onset)
C4 level Not performed
Normal/High
Low
(*Only refers to testing performed within 2 weeks




(*Only refers to testing performed within 2 weeks
before or after AKI onset)
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Did the patient receive PET imaging within 2 weeks Yes
before or after AKI diagnosis? No
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AKI Managment
Questions in this section refer to the initial episode of  ICPi-associated AKI
How was ICPi therapy managed at the time of AKI? Held
Same regimen continued without interruption
Planned ICPi therapy already completed at time of
AKI
Was the AKI treated with glucocorticoids? Yes
No
Why was glucocorticoid therapy withheld?
 
__________________________________________
Date of initiation of glucocorticoid therapy
__________________________________
Was the patient on dialysis at the time of Yes
glucocorticoid initiation? No
Enter the SCr (mg/dl) at the time of glucocorticoid
initiation __________________________________
(Please ensure units for SCr are mg/dl)
Did patient receive intravenous pulse glucocorticoids? Yes
No
Enter number of glucocorticoid pulses received
__________________________________
Enter the cumulative dose of pulse steroids in gram
equivalents  of methylprednisolone (Solumedrol).  For __________________________________
example, if the patient received Solumedrol 500mg IV
daily x 3 days, enter "1.5"
Steroid conversion calculator can be found here:
https://www.mdcalc.com/steroid-conversion-calculator
Enter the initial oral prednisone dose (or in
prednisone equivalent units, in mg) at the time of AKI __________________________________
Steroid conversion calculator can be found here:
https://www.mdcalc.com/steroid-conversion-calculator
Enter the date upon which prednisone was tapered to a
dose ≤10 mg per day __________________________________
Was the patient treated with an immunosuppressive Yes
agent other than/in addition to glucocorticoids? No
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer




Enter the name of the alternative agent, route of
administration, the dose, and the timing in relation  
to steroids (e.g., SCr remained elevated for 7 days __________________________________________
following initiation of prednisone, and therefore
cellcept 1g BID PO was added on day 8, and was
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Treatment Outcomes
Did the patient achieve complete renal recovery? This Yes
is defined as a return of SCr to within 25% of the No
baseline SCr (the nearest value prior to ICPi
initiation). Please limit response to the time period
within 3 months following AKI diagnosis.
Enter the date when complete renal recovery was first
achieved __________________________________
Did the patient require renal replacement therapy? Yes
No
Select the date dialysis was initiated
__________________________________
Was dialysis able to be discontinued? (Note: Select Yes
"No" if patient discontinued dialysis for palliative No
reasons and did not have renal recovery)
Select the date dialysis was discontinued
__________________________________
Enter the nadir SCr (mg/dl) (i.e., the lowest value
achieved) following liberation from dialysis. Limit __________________________________
time period to the 3 months following AKI episode.
(Note: do not use any values from within 7 days of
dialysis)
Enter the nadir SCr (mg/dl) (i.e., the lowest value
achieved) within 3 months following AKI onset. __________________________________
Select the date of the nadir SCr
__________________________________
Enter SCr (mg/dl) at 7 days (+/- 3 days) after the
date of AKI onset __________________________________
(*If no test was performed, enter N/A)
Enter SCr (mg/dl) at 14 days (+/- 3 days) after the
date of AKI onset __________________________________
(*If no test was performed, enter N/A)
Enter SCr (mg/dl) at 21 days (+/- 3 days) from the
date of the initial AKI episode __________________________________
(*If no test was performed, enter N/A)
Enter SCr (mg/dl) at 28 days (+/- 3 days) after the
date of AKI onset __________________________________
(*If no test was performed, enter N/A)
Enter SCr (mg/dl) at 35 days (+/- 3 days) after the
date of AKI onset __________________________________
(*If no test was performed, enter N/A)
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Enter SCr (mg/dl) at 42 days (+/- 3 days) after the
date of AKI onset __________________________________
(*If no test was performed, enter N/A)
Was the patient re-challenged with an ICPi after AKI Yes
No
Why was the patient not re-challenged? Death or transition to hospice
Occurrence of another more severe immune-related
adverse event
Directly because of ICPi-AKI
Progression of disease on the ICPi
The patient was in remission
Other
Please enter another reason why the patient was not
re-challenged with ICPi __________________________________
Enter date of re-challenge
__________________________________
Enter SCr (mg/dl) at time of re-challenge
__________________________________
Note: If the patient was on dialysis at the time of
re-challenge, enter "30"
Enter prednisone dose (if any)  in mg, in prednisone
equivalent units, at time of re-challenge. __________________________________
Note: Enter "0" if patient not on prednisone at time
of re-challenge










Was the patient on a potential tubulointerstitial Yes
nephritis-causing medication at the time of ICPi No
re-challenge (e.g., PPI, NSAIDs, antibiotics)?
If the patient was on one of these medications at the PPIs
time of re-challenge, which one(s) were they on? NSAIDs
Antibiotics
Did ICPi-AKI recur with rechallenge? Yes
No
Note: ICPi-AKI defined as ≥50% increase in SCr from
baseline and attributed to the ICPi.  The baseline SCr
here is the SCr at the time of ICPi re-challenge.
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How long were they continued on immunotherapy, in # of
cycles, from the date of re-challenge? __________________________________
Definition of a cycle: a period of treatment followed
by a period of rest (no treatment) that is repeated on
a regular schedule. For example, treatment given once
followed by three weeks of rest is one treatment cycle
Select date patient first fulfilled criteria for
ICPi-AKI after re-challenge __________________________________
Enter SCr (mg/dl) at time of diagnosis of ICPi-AKI
after re-challenge __________________________________
Enter peak SCr (mg/dl) following ICPi-AKI after
re-challenge __________________________________
How was ICPi therapy managed at the time of ICPi-AKI Held
after re-challenge? Same regimen continued without interruption
Planned ICPi therapy already completed at time of
AKI
Was ICPi-AKI after re-challenge treated with Yes
glucocorticoids? No
Why was glucocorticoid therapy withheld?
 
__________________________________________
Date of initiation of glucocorticoid therapy for
ICPi-AKI after re-challenge __________________________________
Did patient receive intravenous pulse glucocorticoids Yes
for ICPi-AKI after re-challenge? No
Enter number of glucocorticoid pulses received
__________________________________
Enter the cumulative dose of pulse steroids in gram
equivalents  of methylprednisolone (Solumedrol).  For __________________________________
example, if the patient received Solumedrol 500mg IV
daily x 3 days, enter "1.5"
Steroid conversion calculator can be found here:
https://www.mdcalc.com/steroid-conversion-calculator
Enter the initial oral steroid dose (or in prednisone
equivalent units, in mg) at the time of ICPi-AKI __________________________________
Steroid conversion calculator can be found here:
https://www.mdcalc.com/steroid-conversion-calculator
Enter the date upon which prednisone was tapered to a
dose ≤10 mg per day __________________________________
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Was the patient on dialysis at the time of Yes
glucocorticoid initiation? No
Was the patient treated with an immunosuppressive Yes
agent other than/in addition to glucocorticoids? No
Enter the name of the alternative agent, route of
administration, the dose, and the timing in relation  
to steroids (e.g., SCr remained elevated for 7 days __________________________________________
following initiation of prednisone, and therefore
cellcept 1g BID PO was added on day 8, and was
continued for 30 days)
Did the patient achieve complete renal recovery from Yes
ICPi-AKI after re-challenge? This is defined as a No
return of SCr to within 25% of the baseline SCr (the
nearest value prior to ICPi initiation). Please limit
response to the time period within 3 months following
AKI diagnosis.
Enter the date when complete renal recovery was 
achieved after re-challenge. __________________________________
Did patient require dialysis for ICPi-AKI after Yes
re-challenge? No
Enter the date dialysis was initiated
__________________________________
Was dialysis able to be discontinued? (Note: Select Yes
"No" if patient discontinued dialysis for palliative No
reasons and did not have renal recovery)
Select the date dialysis was discontinued
__________________________________
Enter the nadir SCr (mg/dl) (i.e., the lowest value
achieved) following liberation from dialysis. Limit __________________________________
time period to the 3 months following re-challenge
ICPi-AKI episode.
(Note: do not use any values from within 7 days of
dialysis)
Enter the nadir SCr (mg/dl) (i.e., the lowest value
achieved) within 3 months following re-challenge __________________________________
ICPi-AKI onset.
Select the date of nadir SCr
__________________________________
Enter the date of last patient follow-up
__________________________________
Survival status at last follow-up Alive
Deceased
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Enter the most recent SCr (mg/dl) value
__________________________________
Note: Enter 30 if patient on dialysis
Date of most recent SCr value (mg/dl)
__________________________________
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